<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="hbaolong@vip.qq.com" />
  <title>癌症传EN:Knowing the Enemy</title>
  <style>
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      background-color: #1a1a1a;
      border: none;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">癌症传EN:Knowing the Enemy</h1>
<p class="author">hbaolong@vip.qq.com</p>
</header>
<center>
<a href="/3place/azzen">返回首页</a> <a
href="/3place/azzen/mingju.html">本书名句</a> <a
href="/3place/azzen/memo.html">本书注解</a> <a
href="/3place/azzen/index_rich.html">丰富目录</a> <a
href="/3place/azzen/index_readcal.html">同读日历</a> <a
href="/3place/azzen/index_timeline.html">时间线</a> <a
href="/3place/azzen/index_books.html">引用书籍</a> <a
href="/3place/azzen/index_words.html">使用字频</a>
<div id="wx_pic" style="margin:0 auto;display:none;">
<img src='/img/logo.png'/>
</div>
</center>
<h4 id="knowing-the-enemy">Knowing the Enemy</h4>
<p>210 It is said that if you know your enemies: Sun Tzu, The Art of War
(Boston: Shambhala, 1988), 82.</p>
<p>210 a urological surgeon, Charles Huggins: Luis H. Toledo-Pereyra,
“Discovery in Surgical Investigation: The Essence of Charles Brenton
Huggins,” Journal of Investigative Surgery 14 (2001): 251–52; Robert E.
Forster II, “Charles Brenton Huggins (22 September 1901–12 January
1997),” Proceedings of the American Philosophical Society 143, no. 2
(1999): 327–31.</p>
<p>211 Huggins’s studies of prostatic fluid: C. Huggins et al.,
“Quantitative Studies of Prostatic Secretion: I. Characteristics of the
Normal Secretion; the Influence of Thyroid, Suprarenal, and Testis
Extirpation and Androgen Substitution on the Prostatic Output,” Journal
of Experimental Medicine 70, no. 6 (1939): 543–56; Charles Huggins,
“Endocrine-Induced Regression of Cancers.” Science 156, no. 3778 (1967):
1050–54; Tonse N. K. Raju, “The Nobel Chronicles. 1966: Francis Peyton
Rous (1879–1970) and Charles Brenton Huggins (1901–1997), Lancet 354,
no. 9177 (1999): 520.</p>
<p>212 “It was vexatious to encounter a dog”: Huggins,
“Endocrine-Induced Regression.”</p>
<p>213 “Cancer is not necessarily autonomous”: Ibid.</p>
<p>213 “Its growth can be sustained and propagated”: Ibid.</p>
<p>213 In 1929, Edward Doisy, a biochemist: Edward A. Doisy, “An
Autobiography,” Annual Review of Biochemistry 45 (1976): 1–12.</p>
<p>213 diethylstilbestrol (or DES): E. C. Dodds et al., “Synthetic
Oestrogenic Compounds Related to Stilbene and Diphenylethane. Part I,”
Proceedings of the Royal Society of London, Series B, Biological
Sciences 127, no. 847 (1939): 140–67; E. C. Dodds et al., “Estrogenic
Activity of Certain Synthetic Compounds,” Nature 141, no. 3562 (1938):
247–48; Edward Charles Dodds, Biochemical Contributions to
Endocrinology: Experiments in Hormonal Research (Palo Alto, CA: Stanford
University Press, 1957); Robert Meyers, D.E.S., the Bitter Pill (New
York: Seaview/Putnam, 1983).</p>
<p>213 Premarin, natural estrogen purified: Barbara Seaman, The Greatest
Experiment Ever Performed on Women: Exploding the Estrogen Myth (New
York: Hyperion, 2004), 20–21.</p>
<p>213 he could inject them to “feminize” the male body: Huggins,
“Endocrine-Induced Regression”; Charles Huggins et al., “Studies on
Prostatic Cancer: II. The Effects of Castration on Advanced Carcinoma of
the Prostate Gland,” Archives of Surgery 43 (1941): 209–23.</p>
<p>214 George Beatson and breast cancer: George Thomas Beatson, “On the
Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for
a New Method of Treatment, with Illustrative Cases,” Lancet 2 (1896):
104–7; Serena Stockwell, “George Thomas Beatson, M.D. (1848–1933),” CA:
A Cancer Journal for Clinicians 33 (1983): 105–7.</p>
<p>214 only about two-thirds of all women: Alexis Thomson, “Analysis of
Cases in Which Oophorectomy was Performed for Inoperable Carcinoma of
the Breast,” British Medical Journal 2, no. 2184 (1902): 1538–41.</p>
<p>214 “It is impossible to tell beforehand”: Ibid.</p>
<p>215 a young chemist in Chicago: E. R. DeSombre, “Estrogens, Receptors
and Cancer: The Scientific Contributions of Elwood Jensen,” Progress in
Clinical and Biological Research 322 (1990): 17–29; E. V. Jensen and V.
C. Jordan, “The Estrogen Receptor: A Model for Molecular Medicine,”
Clinical Cancer Research 9, no. 6 (2003): 1980–89.</p>
<p>215 Ovarian removal produced many other severe side effects: R.
Sainsbury, “Ovarian Ablation as a Treatment for Breast Cancer,” Surgical
Oncology 12, no. 4 (2003): 241–50.</p>
<p>216 “there was little enthusiasm”: Jensen and Jordan, “The Estrogen
Receptor.”</p>
<p>216 Tamoxifen: Walter Sneader, Drug Discovery: A History (New York:
John Wiley and Sons, 2005), 198–99; G. R. Bedford and D. N. Richardson,
“Preparation and Identification of cis and trans Isomers of a
Substituted Triarylethylene,” Nature 212 (1966): 733–34.</p>
<p>216 Originally invented as a birth control pill: M. J. Harper and A.
L. Walpole, “Mode of Action of I.C.I. 46,474 in Preventing Implantation
in Rats,” Journal of Endocrinology 37, no. 1 (1967): 83–92.</p>
<p>216 tamoxifen had turned out to have exactly the opposite effect: A.
Klopper and M. Hall, “New Synthetic Agent for Induction of Ovulation:
Preliminary Trials in Women,” British Medical Journal 1, no. 5741
(1971): 152–54.</p>
<p>216 Arthur Walpole and breast cancer: V. C. Jordan, “The Development
of Tamoxifen for Breast Cancer Therapy: A Tribute to the Late Arthur L.
Walpole,” Breast Cancer Research and Treatment 11, no. 3 (1988):
197–209.</p>
<p>216 Mary Cole’s tamoxifen trial: M. P. Cole et al., “A New
Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical
Appraisal of ICI46474,” British Journal of Cancer 25, no. 2 (1971):
270–75; Sneader, Drug Discovery, 199.</p>
<p>217 In 1973, V. Craig Jordan: See V. C. Jordan, Tamoxifen: A Guide
for Clinicians and Patients (Huntington, NY: PRR, 1996). Also see V. C.
Jordan, “Effects of Tamoxifen in Relation to Breast Cancer,” British
Medical Journal 6075 (June 11, 1977): 1534–35.</p>
<h6 id="阅读日期-2026年01月20日-2026年01月20日-共-1-天">阅读日期：
2026年01月20日-2026年01月20日 共： 1 天</h6>
<script src="https://giscus.app/client.js"
        data-repo="hbaolong/hbaolong.github.io"
        data-repo-id="R_kgDOLetDQg"
        data-category="General"
        data-category-id="DIC_kwDOLetDQs4CfLEl"
        data-mapping="url"
        data-strict="0"
        data-reactions-enabled="1"
        data-emit-metadata="1"
        data-input-position="top"
        data-theme="preferred_color_scheme"
        data-lang="zh-CN"
        crossorigin="anonymous"
        async>
</script>
</body>
</html>
